Search for content, post, videos

Alligator announces authorization to initiate Phase 2 trial

Søren Bregenholt
Alligator Bioscience has announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application, allowing the company to initiate the OPTIMIZE-2 Phase 2 trial evaluating its lead asset mitazalimab in urothelial carcinoma. This open-label, m
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.